CJC-1295

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH, also called GRF) consisting of the first 29 amino acids of GHRH with four amino acid substitutions designed to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). Two variants exist in research: CJC-1295 with Drug Affinity Complex (DAC) for extended half-life through albumin binding, and CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF). Published clinical studies have demonstrated that CJC-1295 DAC can sustain elevated GH and IGF-1 levels for up to 14 days after a single injection, making it a significant tool in growth hormone axis research.

For research use only · Not FDA/EMA approved · Not for human consumption

Mechanism of Action

CJC-1295 activates the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating growth hormone synthesis and secretion through adenylyl cyclase activation and cAMP-dependent protein kinase A (PKA) signaling. The four amino acid substitutions (Ala2→D-Ala, Asn8→Asn(Me), Gly15→Ala, Met27→Leu) confer resistance to DPP-IV cleavage. The DAC variant contains a maleimidopropionic acid linker that forms a covalent bond with albumin in vivo, extending the elimination half-life from approximately 30 minutes (without DAC) to approximately 8 days (with DAC). Published research describes preserved pulsatile GH release pattern when combined with GH secretagogues like Ipamorelin.

For research use only · Not FDA/EMA approved · Not for human consumption

Key Research Areas

• Sustained growth hormone and IGF-1 elevation in clinical studies
• GHRH receptor pharmacology and DPP-IV resistant analogs
• Synergistic GH release with growth hormone secretagogues
• Body composition and metabolic effects in clinical settings
• Extended pharmacokinetic profiles via Drug Affinity Complex technology
• Age-related GH decline and somatopause research

For research use only · Not FDA/EMA approved · Not for human consumption

Published Studies (5 cited)

For research use only · Not FDA/EMA approved · Not for human consumption

Dosage in Published Research

Published clinical studies have investigated CJC-1295 DAC at doses of 30, 60, and 125 μg/kg via subcutaneous injection, administered once or twice weekly. CJC-1295 without DAC (Mod-GRF) has been studied at 1–2 μg/kg per administration in research settings, typically combined with a GH secretagogue. All dosing information is from published literature only.

For research use only · Not FDA/EMA approved · Not for human consumption

Storage & Handling

Store lyophilized CJC-1295 at -20°C. Reconstituted solutions at 2–8°C. CJC-1295 with DAC: use within 14 days after reconstitution. CJC-1295 without DAC: use within 7 days. Protect from light and heat.

For research use only · Not FDA/EMA approved · Not for human consumption

Safety Profile (Literature Only)

Published Phase 1/2 clinical studies reported injection site reactions, facial flushing, and transient GI effects as the most common adverse events. CJC-1295 DAC was generally well-tolerated at investigated doses. Note: one death was reported in a clinical trial participant, though causality was not definitively established. Further large-scale safety trials were not published. This compound is for laboratory research use only.

For research use only · Not FDA/EMA approved · Not for human consumption